ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics

Roche Leads But Rivals Could Have Efficacy Edge

 
• By Andrew McConaghie

Roche looks set to gain first and second place in the race to bring CD3xCD20s to market – but Genmab and AbbVie have a strong challenger.

ASCO 2019
The ASCO meeting returns to an in-person format in Chicago for the first time since 2019. • Source: ASCO

More from Business

More from Scrip